Analysing Oncology Specialist Prescribing trends into ESMO

Based on the IQVIA BrandImpact solid tumours database as of September 2026, we analyse market share and prescribing dynamics across non-small cell lung cancer, breast cancer, prostate cancer, bladder cancer, colorectal cancer and melanoma ahead of the ESMO 2026 conference. In NSCLC, share dynamics remain broadly stable in earlier lines, led by Keytruda, while targeted therapies gain share in later lines; emerging modalities such as PD-1xVEGF could drive more significant reshaping. In breast cancer, Kisqali leads 1L HR+/HER2- and is expanding in adjuvant disease, while Enhertu plus Perjeta is reshaping 1L HER2+ and Enhertu maintains clear leadership in 2L+ HR-/HER2+. In prostate cancer, Nubeqa leads nmCRPC and 1L mCSPC, Xtandi leads 1L mCRPC and Pluvicto leads 2L mCRPC. Keytruda plus Padcev dominates bladder cancer, with incremental gains from subcutaneous Keytruda Qlex plus Padcev. Colorectal cancer remains relatively stable and chemotherapy-led, and melanoma remains dominated by PD-1-